The ANDA for the PEG 3350 laxative was withdrawn by the FDA because:

The ANDA for the PEG 3350 laxative was withdrawn by the FDA because:

• A. There was no meaningful difference between Rx and OTC
• B. Sponsor failed to provide data
• C. Product failed stability testing
• D. There were safety concerns requiring reformulation

Answer: (A)

The key idea is that regulators treat prescription and OTC versions of the same drug as the same product when there is no real difference in how they work or are used. If the active ingredient, strength, dosage form, labeling, safety profile, and intended use are essentially the same for both prescription and OTC versions, there isn’t a regulatory benefit to keeping two separate approvals. In that situation, the FDA may withdraw the prescription-version approval because it adds no unique value and could cause confusion or redundancy in the market. For PEG 3350 laxative, the Rx and OTC formulations were found to be essentially the same in composition and labeling, so there was no meaningful difference to justify maintaining the Rx ANDA.

The key idea is that regulators treat prescription and OTC versions of the same drug as the same product when there is no real difference in how they work or are used. If the active ingredient, strength, dosage form, labeling, safety profile, and intended use are essentially the same for both prescription and OTC versions, there isn’t a regulatory benefit to keeping two separate approvals. In that situation, the FDA may withdraw the prescription-version approval because it adds no unique value and could cause confusion or redundancy in the market. For PEG 3350 laxative, the Rx and OTC formulations were found to be essentially the same in composition and labeling, so there was no meaningful difference to justify maintaining the Rx ANDA.